Dyne Therapeutics
Dyne Therapeutics is developing innovative therapeutics for genetically driven neuromuscular diseases, focusing on muscle and CNS targets. The company is engaged in clinical programs for DMD and DM1, with preclinical projects for FSHD and Pompe disease.
Headquarters
Waltham, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
Dyne Therapeutics is a biotechnology company developing nucleic acid–based therapies for genetically driven neuromuscular diseases. Leveraging its proprietary FORCE™ platform, Dyne aims to address the root cause of disease and deliver functional improvement for people living with conditions such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). The company advances a pipeline of therapeutics from discovery through clinical development with the mission of transforming the lives of patients with rare neuromuscular diseases.
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN)
2 days ago
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
3 days ago
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8%
22 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Dyne Therapeutics.
150-patient Dyne trial focuses on myotonic dystrophy daily function
3 days ago
Associate Director, Drug Substance Development & Manufacturing
Entrada Therapeutics
Senior Scientist, CMC Downstream Process Development
Neurocrine Biosciences
Associate Scientist II / Senior Associate Scientist, Nanoparticle Process Development
Strand Therapeutics
Associate Director, CMC
AstraZeneca
Scientist II / Senior Scientist, I, tLNP Process Development
AbbVie
Associate Director, CMC
AstraZeneca